All In Biotech

Drug Trial Radar · NCT05646719

Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia

Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase 3 Study of the Safety and Efficacy of Nyxol (Phentolamine Ophthalmic Solution 0.75%) as a Single Agent and With Adjunctive Low-Dose Pilocarpine Hydrochloride Ophthalmic Solution 0.4% in Subjects With Presbyopia

Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 333 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

333

Actual

Start

Dec 22, 2022

Primary completion

Oct 11, 2023

Study completion Oct 11, 2023

Sponsor

Lead sponsor
Opus Genetics, IncIndustry
Sponsor type
Industry
First posted
Dec 12, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objectives of this study are: To evaluate the safety and efficacy of Nyxol alone and with adjunctive low dose pilocarpine to improve distance-corrected near visual acuity (DCNVA) in subjects with presbyopia.

Conditions

  • Presbyopia

Interventions

  • Phentolamine Opthalmic Solution 0.75%Drug

    phentolamine ophthalmic solution 0.75% (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist

  • PlaceboOther

    Vehicle for Phentolamine Ophthalmic Solution

  • Low dose pilocarpineDrug

    Pilocarpine hydrochloride ophthalmic solution 0.4%

  • Low dose pilocarpine vehicleOther

    Vehicle for low dose pilocarpine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent of Subjects With ≥ 15 Letters of Improvement in Photopic Binocular DCNVA and With < 5 Letters of Loss in Photopic Binocular BCDVA in Nyxol-treated SubjectsTime frame: Baseline at 30 min post-LDP/vehicle comparing subjects treated with Nyxol + LDP to subjects treated with placebo + LDP vehicle at Visit 5 (Stage 2 Day 8)

Locations

26 sites in 1 country. Site status is shown where the registry gives one.

  • Phoenix, AZ

    Phoenix, Arizona

  • Azusa, CA

    Azusa, California

  • Newport Beach, CA

    Newport Beach, California

  • Northridge, CA

    Northridge, California

  • Delray Beach, FL

    Delray Beach, Florida

  • Longwood, FL

    Longwood, Florida

  • Roswell, GA

    Roswell, Georgia

  • Lake Villa, IL

    Lake Villa, Illinois

  • Pittsburg, KS

    Pittsburg, Kansas

  • Shawnee Mission, KS

    Shawnee Mission, Kansas

  • Bloomington, MN

    Bloomington, Minnesota

  • Chesterfield, MO

    Chesterfield, Missouri

  • Kansas City, MO

    Kansas City, Missouri

  • Saint Louis, MO

    St Louis, Missouri

  • Rochester, NY

    Rochester, New York

  • Smithtown, NY

    Smithtown, New York

  • Garner, NC

    Garner, North Carolina

  • Fargo, ND

    Fargo, North Dakota

  • Athens, OH

    Athens, Ohio

  • Cranberry Township, PA

    Cranberry Township, Pennsylvania

  • New Freedom, PA

    New Freedom, Pennsylvania

  • Sioux Falls, SD

    Sioux Falls, South Dakota

  • Memphis, TN

    Memphis, Tennessee

  • Austin, TX

    Austin, Texas

  • Houston, TX

    Houston, Texas

  • San Antonio, TX

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.